Endoglycan Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of Endoglycan monoclonal antibodies for research focused on understanding endoglycan's role in various biological processes. Endoglycan monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Endoglycan, also known as CD168, is a glycoprotein that plays a crucial role in cell adhesion and migration, particularly during immune responses and tissue remodeling. CD168 expression is associated with various physiological and pathological processes, including inflammation and cancer progression. Understanding CD168 function is essential for elucidating its potential as a therapeutic target in diseases characterized by aberrant cell behavior. Researchers worldwide utilize Endoglycan monoclonal antibodies to investigate cellular mechanisms and pathways involved in disease progression. Advanced research techniques and protocols enable precise detection and analysis of CD168 in multiple experimental settings. Ongoing studies with Endoglycan monoclonal antibodies continue to reveal new insights about cellular processes and disease mechanisms. Santa Cruz Biotechnology monoclonal antibodies support scientific discovery by enabling researchers to advance their understanding of fundamental biological processes and potential therapeutic applications.